
|Articles|September 1, 2001
- Pharmaceutical Executive-09-01-2001
- Volume 0
- Issue 0
Profits and Promotion Under Attack
As policy makers struggle to devise a pharmacy benefit for Medicare patients, pressure mounts to impose spending limits on medications. In turn, consumer activists are challenging industry’s longtime claim that price controls will reduce investment in R&D for life-saving therapies.
Advertisement
Articles in this issue
over 24 years ago
New Playing Fieldsover 24 years ago
Inefficiencies: Cutting Through the Jungleover 24 years ago
Legislation: EC Proposes Changesover 24 years ago
Flexing Their Budgets: Big Pharma Spend Trendsover 24 years ago
Media Mix Town Meeting 2001: Much Ado About MediaAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
The Risks and Benefits of FDA Reviewing Real-Time Data
3
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5




